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Abstract The CD8+ T cell clone 5F1 produces interleukin 10
(IL-10) and interferon Q (IFN-Q) in response to stimulation with a
peptide corresponding to region 142^149 of bovine Ks1-casein
(p142^149). Ninety analog peptides derived from p142^149 with
single amino acid substitutions of putative T cell receptor contact
residues were prepared to examine whether production of IL-10
and IFN-Q by 5F1 can be altered by stimulation with these
peptides. We found that some peptides triggered only IL-10
production whereas others induced production of IFN-Q alone or
both of these cytokines. Peptides inducing IFN-Q production
triggered both cytotoxicity and a proliferative response, whereas
peptides inducing production of IL-10 but not IFN-Q triggered
neither of these responses. Our results clearly demonstrate that
the signaling pathway required for IL-10 production in CD8+ T
cells differs from that required for IFN-Q production. The distinct
cellular signals for IL-10 production appear to be independent of
those for cytotoxicity and the proliferative response of CD8+ T
cells.
z 1998 Federation of European Biochemical Societies.
Key words: Altered peptide ligand; CD8 T lymphocyte;
Interleukin 10; Interferon Q ; Cytotoxicity
1. Introduction
CD8 T cells mostly recognize endogenously synthesized
antigens presented by MHC class I molecules; however,
some CD8 T cells can be triggered by exogenous antigens
[1^5]. These exogenous antigen-speci¢c CD8 T cells are con-
sidered to participate in regulation of the immune system via
soluble factors. It is accepted that CD4 T cells are classi¢ed
into two subsets each with a particular cytokine production
pattern: Th1 cells producing IL-2, IFN-Q, and lymphotoxin,
and Th2 cells producing IL-4, IL-5, IL-6, IL-10, and IL-13 [6].
In contrast to CD4 T cells, the exogenous antigen-speci¢c
CD8 T cells produce IL-10 or IL-4 in addition to Th1-type
cytokines [5]. We have previously described the ¢nding that
bovine Ks1-casein, a major milk allergen, can induce speci¢c
CD8 T cells that produce IL-10 in addition to Th1-type
cytokines [7^11]. Our studies of arti¢cial stimulation of the
responding CD8 T cells, such as with anti-CD3 antibody,
or dibutyryl cAMP (Bt2cAMP) plus a calcium ionophore,
have provided evidence suggesting that separate cellular sig-
nals are required for IL-10 or Th1-type cytokine production
[12].
Recent studies showed that T cell activation is not a simple
on-o¡-type event; rather, qualitative changes in T cell re-
sponses can be induced by amino acid substitutions in anti-
genic peptides. Some analog peptides having substitutions of
amino acid residues involved in interaction with the T cell
receptor (TCR) can elicit T cell responses qualitatively di¡er-
ent from those produced by the original peptide. These pep-
tides are called altered peptide ligands [13]. For example,
some analog peptides induce cytokine production without
proliferation [14], cytotoxicity without proliferation and cyto-
kine production [15,16], alteration of the pattern of cytokine
production [17], or anergy [18]. In this study, we demonstrate
the selective induction of IL-10 production or IFN-Q produc-
tion in an Ks1-casein-speci¢c CD8 T cell clone, using a panel
of 90 analogs of a peptide corresponding to region 142^149 of
bovine Ks1-casein (p142^149) each with a single amino acid
substitution at a TCR contact residue.
2. Materials and methods
2.1. Animals
Female C57BL/6 mice were purchased from Clea Japan Inc. (To-
kyo, Japan).
2.2. Antigens
Bovine Ks1-casein was puri¢ed from fresh raw skim milk, and was
digested with trypsin (Sigma, St. Louis, MO, USA) as previously
described [19]. p142^149 was synthesized by means of a peptide syn-
thesizer (430A; Applied Biosystems, Foster City, CA, USA), and
puri¢ed by reversed-phase HPLC. Single amino acid substituted pep-
tide analogs of p142^149 (Table 1) were obtained from Chiron Mim-
otopes Pty Ltd. (Clayton, Vic., Australia).
2.3. CD8+ T cell clone 5F1
An Ks1-casein-speci¢c CD8 T cell clone, 5F1, was used in this
study [11]. This clone was maintained in a conditioned RPMI 1640
medium which was supplemented with 10% FCS, 5U1035 M 2-mer-
captoethanol, 100 U/ml penicillin, 100 Wg/ml streptomycin, and 10% T
cell growth factor (TCGF) [7]. These cells were stimulated with irra-
diated syngeneic spleen cells as antigen-presenting cells (APC) in the
presence of trypsin-digested Ks1-casein at 10 Wg/ml every 10 days.
2.4. Enzyme-linked immunosorbent assay (ELISA)
T cells (4U104/well) were plated into 96-well plates with irradiated
spleen cells (2U105/well) and each peptide in 200 Wl of medium. The
culture supernatants were collected 48 h later. The levels of IFN-Q and
IL-10 in the culture supernatants were assessed by two-site ELISA as
described previously [11]. In brief, to detect IFN-Q, plates (MaxiSorp;
NUNC, Roskilde, Denmark) were coated with anti-IFN-Q mAb R4-
6A2 and IFN-Q bound was detected by means of biotinylated anti-
IFN-Q mAb XMG1.2. To detect IL-10, anti-IL-10 mAb JES5-2A5
and biotinylated anti-IL-10 mAb SXC-1 were used as the coating
antibody and detecting antibody, respectively. The detection limits
for IFN-Q and IL-10 were 1 U/ml and 1 U/ml, respectively.
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2.5. Cytotoxicity assay
Cytotoxicity was assayed by measuring the release of lactate dehy-
drogenase (LDH) into supernatants using an enzymatic assay kit
(Cyto Tox 96 Assay kit: Promega, Madison, WI, USA) according
to the manufacturer’s instructions. Data are expressed as the percent-
age of maximal release observed, after subtraction of the release
induced by targets pulsed with no peptide. Ten thousand EL-4 cells
(ATCC) were used as the target cells at an e¡ector:target ratio of
10.
2.6. T cell proliferation assay
The proliferation of T cells was determined by measuring the up-
take of [3H]thymidine. T cells (4U104/well) were stimulated by irra-
diated spleen cells (2U105/well) and each peptide in 200 Wl of medium.
The cells were cultured for 48 h and pulsed with 18.5 kBq of
[3H]thymidine (248 GBq/nmol; New England Nuclear, Boston, MA,
USA) during the last 20 h.
3. Results
3.1. Analog peptides selectively induced IL-10 production
or IFN-Q production in an Ks1-casein-speci¢c CD8
+ T cell
clone
The Ks1-casein speci¢c CD8 T cell clone 5F1 produces IL-
10 and IFN-Q in response to region 142^149 of Ks1-casein
complexed with a Kb molecule [20]. The sequence of this
region (Leu-Ala-Tyr-Phe-Tyr-Pro-Glu-Leu) is in complete ac-
cordance with the proposed Kb motif sequence (X-X-Tyr-X-
Phe/Tyr-X-X-Leu/Met, where bold letters indicate anchor res-
idues) [21]. From this motif, the potential TCR contact resi-
dues of p142^149 are assumed to be Leu at position 142, Ala
at position 143, Phe at position 145, Pro at position 147, and
Glu at position 148. On the basis of this information, we
designed 90 analog peptides each with a substitution in these
TCR contact residues (for a list of these peptides, see Table 1).
To evaluate the e¡ects of these single amino acid substitu-
tions, the amounts of IL-10 and IFN-Q produced by 5F1 in
response to stimulation with each of the 90 analog peptides
were determined by ELISA. Fig. 1 shows representative data
for each analog peptide capable of triggering IL-10 and/or
IFN-Q production. We can categorize the analog peptides
into four groups: (1) peptides triggering production of IL-10
but not IFN-Q such as A143L or P147I, (2) peptides triggering
production of IFN-Q but not IL-10 such as A143S or E148H,
(3) peptides triggering production of both IL-10 and IFN-Q
such as L142I or F145H, and (4) peptides failing to trigger
production of either of the cytokines examined. This is the
¢rst demonstration of discrimination of the signal requirement
for IL-10 production from that for IFN-Q production by ana-
log peptides.
Next, the relationship between peptide concentration and
the induction of IL-10 and IFN-Q production was examined
using A143L, a peptide classi¢ed into group 1, and p142^149.
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Fig. 1. Analog peptides change the cytokine production pattern of 5F1 cells. 5F1 cells (4U104/well) were stimulated with APC (2U105/well)
and 10 WM p142^149 or analog peptides. After a 48-h culture period, the levels of IFN-Q and IL-10 in the culture supernatants were assessed
by ELISA. Shown here are representative results for analog peptides which induced IL-10 and/or IFN-Q production: peptides inducing produc-
tion of both IL-10 and IFN-Q (hatched bars), IL-10 but not IFN-Q (closed bars), or IFN-Q but not IL-10 (open bars). The data are expressed
as relative values compared with the level of each cytokine produced upon stimulation with p142^149.
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As shown in Fig. 2, A143L optimally induced IL-10 produc-
tion at 0.5 WM and induced no IFN-Q production even at high
peptide concentrations. In contrast, p142^149 induced both
IL-10 and IFN-Q production at each concentration examined,
as shown in Fig. 2. At lower concentrations, p142^149 in-
duced weak production of both IL-10 and IFN-Q, and when
the concentration of p142^149 was further reduced neither of
them was produced (data not shown). Thus, selective induc-
tion of IL-10 was not observed when 5F1 cells were stimu-
lated with p142^149.
3.2. Analog peptides which triggered only IL-10 production
induced neither cytotoxicity nor a proliferative response
We next assessed the relationship between the putative IL-
10 speci¢c cellular signals and the signals for cytotoxicity. 5F1
cells showed signi¢cant cytolytic activity for p142^149-pulsed
EL4 cells (Fig. 3a). Each of ¢ve peptides, A143I, A143L,
P147I, P147L, and P147F, which induced only IL-10 produc-
tion, was unable to induce cytolytic activity, whereas analog
peptides which induced IFN-Q production could induce cyto-
toxicity (Fig. 3a).
5F1 cells showed a proliferative response to trypsin-digested
Ks1-casein [20] and to p142^149 (Fig. 3b). The analog peptides
which induced only IL-10 production did not induce prolifer-
ation, whereas the analog peptides which triggered IFN-Q pro-
duction induced a proliferative response (Fig. 3b). These re-
sults indicate that peptides A143I, A143L, P147I, P147L and
P147F selectively activated the signaling pathway for IL-10
production, which is independent of that for cytotoxicity
and proliferation of the responding CD8 T cells.
4. Discussion
In this study, we have shown that single amino acid sub-
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Fig. 2. IL-10 and IFN-Q production by 5F1 cells upon stimulation with various concentrations of A143L or p142^149. 5F1 cells (4U104/well)
were stimulated with the indicated concentrations of A143L or p142^149 in the presence of APC (2U105/well). After a 48-h culture period, the
levels of IL-10 and IFN-Q in the culture supernatants were assessed by ELISA.
Table 1
List of peptides used in this study
1Dashes indicate identity with the p142^149 sequence.
2A peptide corresponding to region 142- -149 of bovine Ks1-casein.
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stituted analogs of an antigenic peptide could induce separate
production of either IL-10 or IFN-Q from a CD8 T cell
clone. This indicates that a single amino acid substitution in
an antigenic peptide can modulate cytokine production by a
CD8 T cell clone in an antigen-speci¢c manner. Further-
more, analog peptides triggering production of IFN-Q induced
cytotoxicity and proliferation as well, while those inducing IL-
10 production without triggering IFN-Q production did not.
Our results demonstrate that the signal transduction pathway
for triggering of IL-10 production and the signaling require-
ments for induction of IFN-Q production, cytotoxicity and
proliferation are distinct in CD8 T cells.
We demonstrated in our previous study that production of
IL-10 and IFN-Q requires distinct signals in a CD8 T cell
clone [12]. Stimulation with Bt2cAMP enhanced the produc-
tion of IL-10 but not IFN-Q. This indicates that IL-10 pro-
duction but not IFN-Q production requires activation of a
cAMP-dependent pathway. The analog peptides triggering
IL-10 production alone may selectively activate this cAMP
pathway. Recently, Madrenas et al. [22] and Sloan-Lancaster
et al. [23] analyzed intracellular signaling events in T cells
responding to altered peptide ligands and reported a distinct
pattern of j chain phosphorylation accompanied by a failure
to activate ZAP-70 kinase. Such a di¡erence in signals
through TCR probably in£uences the di¡erent activation pat-
terns of the CD8 T cells observed in this study. Re¢ned
experiments using selective inhibitors for each signaling path-
way may clarify whether these pathways are involved in the
selective induction of IL-10 production.
For CD8 T cell clones, it has been reported that altered
peptide ligands selectively induced cytotoxicity but not prolif-
eration and cytokine production [16,24]. Valitutti et al. have
demonstrated that di¡erent biological responses of human
CD8 T cells, e.g. cytotoxicity, cytokine production, and pro-
liferative response, are elicited depending upon the level of
TCR occupancy [25]. They observed that cytotoxicity could
be induced by the lowest occupancy, implying that induction
of cytotoxicity has the least signal requirements. Therefore,
the above examples of partial activation may be attributed
to insu⁄cient signals transduced through TCR engaged with
altered ligands. In the present study, we could dissect IL-10
production from the rest of CD8 T cell responses; some
peptides induced only IL-10 production, while others induced
the responses other than IL-10 production. Furthermore, a
peptide which induced only IL-10 production did not induce
IFN-Q production even at high peptide concentrations, while
p142^149 did not show selective induction of IL-10 at low
concentrations. Therefore, the selective induction of CD8 T
cell responses cannot be explained by hierarchical induction of
TCR-mediated signal transduction pathways, but indicate
that distinct signaling pathways were selectively induced by
the variant peptides. Our results clearly demonstrate a novel
type of activation of CD8 T cells induced by altered peptide
ligands.
The selective induction of CD8 T cell responses by altered
antigenic peptides as shown here not only facilitates under-
standing of the relationship between signaling pathways spe-
ci¢c for production of a cytokine and antigenic stimulation,
but also could be applied as a novel means of controlling the
cytokine balance via CD8 T cells. In certain immune dis-
eases, either the Th1-type or the Th2-type immune response
is dominant: for example, multiple sclerosis and rheumatoid
arthritis are Th1-dominant diseases, and allergies are Th2-
dominant diseases [26]. It has been reported that IFN-Q selec-
tively inhibits Th2-type responses [6], while IL-10 inhibits re-
sponses of Th1 cells [27]. Thus, CD8 T cells secreting IL-10
and/or IFN-Q have the potential to correct the imbalance in
Th1-Th2 responses that may be responsible for the deleterious
immune responses. Moreover, peptides which are recognized
by CD8 T cells have a low possibility of being recognized by
CD4 T cells, because of the distinct MHC-molecule require-
ments. Therefore, peptides inducing CD8 T cell responses
could be used without the risk of accidental activation of
CD4 T cells. If we can choose suitable analog peptides cap-
able of modifying the cytokine production pattern of CD8 T
cells in particular immune diseases, this strategy will lead to
clinical application of altered peptide ligands as a CD8 T
cell-mediated immunotherapy.
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Fig. 3. Cytolytic activity (a) and proliferation (b) of 5F1 cells in response to the analog peptides. a: EL-4 cells (1U104/well) were pulsed for 1 h
with each peptide at a concentration of 10 WM, and plated with 5F1 cells (1U105/well) in 96-well plates. After a 4-h incubation period, super-
natants were recovered and assayed for the presence of LDH released by the target cells. The standard deviation was less than 10% of maxi-
mum in each instance. b: 5F1 cells (4U104/well) were cultured with APC (2U105/well) and 10 WM p142^149 or analog peptides for 48 h, and
[3H]thymidine uptake during the last 20 h was measured. The results are expressed as relative values compared with the level of [3H]thymidine
uptake observed upon stimulation with p142^149.
M. Kohyama et al./FEBS Letters 423 (1998) 138^142 141
References
[1] Fong, T.A. and Mosmann, T.R. (1990) J. Immunol. 144, 1744^
1752.
[2] Prystowsky, M.B., Ely, J.M., Beller, D.I., Eisenberg, L., Gold-
man, J., Goldman, M., Goldwasser, E., Ihle, J., Quintans, J.,
Remold, H., Vogel, S.N. and Fitch, F.W. (1982) J. Immunol.
129, 2337^2344.
[3] Minigari, M.C., Moretta, L., Maggi, E., Pantaleo, G., Gerosa,
F., Romagnani, S. and Moretta, L. (1984) Eur. J. Immunol. 14,
1066^1069.
[4] Paliard, X., de Waal Male¢jt, R., Yssel, H., Blanchard, D., Chre-
tien, I., Abrams, J., de Vries, J.E. and Spits, H. (1988) J. Immu-
nol. 141, 849^855.
[5] Salgame, P., Abrams, J.S., Clayberger, C., Goldstein, H., Convit,
J., Modlin, R.L. and Bloom, B.R. (1991) Science 254, 279^
282.
[6] Mosmann, T.R. and Co¡man, R.L. (1989) Annu. Rev. Immunol.
7, 145^173.
[7] Hisatsune, T., Enomoto, A., Nishijima, K., Minai, Y., Asano,
Y., Tada, T. and Kaminogawa, S. (1990) J. Immunol. 145, 2421^
2426.
[8] Hisatsune, T., Minai, Y., Nishijima, K., Enomoto, A., Moore,
K.W., Yokota, T., Arai, K. and Kaminogawa, S. (1992) Lym-
phokine Cytokine Res. 11, 87^93.
[9] Hisatsune, T., Nishijima, K., Kohyama, M., Kato, T. and Ka-
minogawa, S. (1995) J. Immunol. 154, 6238^6245.
[10] Nishijima, K., Hisatsune, T., Choi, C.Y. and Kaminogawa, S.
(1995) Biosci. Biotechnol. Biochem. 59, 2274^2276.
[11] Nishijima, K., Kohyama, M., Hisatsune, T., Kato, H., Kakehi,
M. and Kaminogawa, S. (1997) Biosci. Biotechnol. Biochem. 61,
1156^1162.
[12] Minai, Y., Goto, M., Kohyama, M., Hisatsune, T., Nishijima, K.
and Kaminogawa, S. (1996) Cell. Immunol. 172, 200^204.
[13] Sloan-Lancaster, J. and Allen, P.M. (1996) Annu. Rev. Immunol.
14, 1^27.
[14] Evavold, B.D. and Allen, P.M. (1991) Science 252, 1308^1310.
[15] Evavold, B.D., Sloan-Lancaster, J., Hsu, B.L. and Allen, P.M.
(1993) J. Immunol. 150, 3131^3140.
[16] Hoºllsberg, P., Weber, W.E.J., Dangond, F., Batra, V., Sette, A.
and Ha£er, D.A. (1995) Proc. Natl. Acad. Sci. USA 92, 4036^
4040.
[17] Sad, S., Marcotte, R. and Mosmann, T.R. (1995) Immunity 2,
271^279.
[18] Sloan-Lancaster, J., Evavold, B.D. and Allen, P.M. (1993) Na-
ture 363, 156^159.
[19] Shimizu, M., Ametani, A., Kaminogawa, S. and Yamauchi, K.
(1986) Biochim. Biophys. Acta 869, 256^264.
[20] Nishijima, K., Hisatsune, T., Kato, H., Kohyama, M., Kakehi,
M., Hachimura, S. and Kaminogawa, S. (1998) Cytotechnology
(in press).
[21] Falk, K., Roºzschke, O., Stevanovic, S., Jung, G. and Rammen-
see, H.-G. (1991) Nature 351, 290^296.
[22] Madrenas, J., Wange, R.L., Wang, J.L., Isakov, N., Samelson,
L.E. and Germain, R.N. (1995) Science 267, 515^518.
[23] Sloan-Lancaster, J., Shaw, A.S., Rothbard, J.B. and Allen, P.M.
(1994) Cell 79, 913^922.
[24] Martin, S., Kohler, H., Weltzien, H.U. and Leipner, C. (1996)
J. Immunol. 157, 2358^2365.
[25] Valitutti, S., Muller, S., Dessing, M. and Lanzavecchia, A. (1996)
J. Exp. Med. 183, 1917^1921.
[26] Mosmann, T.R. and Sad, S. (1996) Immunol. Today 17, 138^146.
[27] Fiorentino, D.F., Bond, M.W. and Mosmann, T.R. (1989) J. Exp.
Med. 170, 2081^2095.
FEBS 19850 20-2-98
M. Kohyama et al./FEBS Letters 423 (1998) 138^142142
